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(54) Syntesis of tetrodotoxin, its analogues and intermediates thereof
(57) The invention provides for the synthesis of Tet-
rodotoxin, its tautomers, enantiomers, distercoisomer or
analogues through the use of spirolactam compounds of
formula II
as starting material, by incorporation of a guanidine (or
similar) residue to a compound of formula II prior to the
formation of an orthoester, or the use of a compound of
formula VII as starting material.
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Description
FIELD OF THE INVENTION
[0001] The present invention relates to a synthesis of Tetrodotoxin and analogues thereof. New compounds useful
as intermediates are also disclosed.
BACKGROUND OF THE INVENTION
[0002] In the present application the following numbering will be used (see figure 1, page 7497 in Sato, K.; Akai, S.;
Sugita, N.; Ohsawa, T.; Kogure, T.; Shoji, H.; Yoshimura, J. J. Org. Chem. 2005, 70, 7496-7504):
[0003] Tetrodotoxin (TTX), Octahydro-12-(hydroxymethyl)-2-imino-5,9:7, 10a-dimethano-10aH-[1,3]dioxocino[6,5-d]
pyrimidine-4,7,10,11,12-pentol, is a potent neurotoxin which selectively binds to sodium channel proteins inhibiting its
function in the cell membrane. Tetrodotoxin was first isolated in 1909 from the ovaries of the puffer fish, and named
after the puffer fish family "Tetraodontidae". Despite being a small molecule, it has an extremely complex structure
characterised by a dioxaadamantane skeleton, a guanidine residue at C2 which is part of a hemiaminal at C4, and an
orthoacid bridge at C10.
[0004] Due to its novel structure and high density of functional groups, only after extensive efforts, Hirata-Goto et al.
(Goto, T.; Kishi, Y.; Takahashi, S.; Hirata, Y. Tetrahedron 1965, 21, 2059-2088), Tsuda et al, (Tsuda, K.; Tkuma, S.;
Kawamura, M.; Tachikawa, K.; Sakai, K.; Tamura, C.; Amakasu, O. Chem. Pharm. Bull. 1964, 12, 1357-1374) and
Woodward et al. (Woodward, R. B. Pure Appl. Chem. 1964, 9, 49-74; Woodward, R. B.; Gougoutas, J. Z. J. Am. Chem.
Soc. 1964, 86, 5030) independently arrived at the same structure in 1964. Finally, in 1970 absolute stereochemistry
was determined unambiguously by X-ray crystallographic analysis of its derivative (Furusaki, A.; Tomic, Y.; Nitta, 1. Bull.
Chem. Soc. Jpn. 1970, 43, 3325-3331).
[0005] Tetrodotoxin blocks diffusion of sodium through the sodium channel, preventing depolarization and propagation
of action potentials in nerve cells. The TTX-Na Channel binding site is extremely tight (Kd = 10-10 nM). Therefore it is
an essential tool in pharmacological studies related to sodium channel proteins.
[0006] Further, Tetrodotoxin, due to its analgesic properties, is a promising new drug candidate in the field of pain
management. It is currently in phase III clinical trials for cancer pain.
[0007] Extraction and purification of natural TTX is complicated, and dependent on the availability of the right animal
source. Therefore there is an existing need of providing larger amounts of Tetrodotoxin and its analogues, and researchers
seek new cost effective and efficient synthesis. Up to the date, only a handfull of total synthesis has been reported.
[0008] The first total synthesis of Tetrodotoxin was reported by Kishi in 1972 and afforded Tetrodotoxin as a racemic
mixture after 29 steps in a 0.66% overall yield (Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.;
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Tetrahedron Lett. 1970, 59, 5127-5128; Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, 11.; Tanino,
H.; Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9217-9219; Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi,
H.; Tanino, H.; Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9219-9220; Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.;
Inoue, S.; Kakoi, H.; Tanino, H.; Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9220-9221).
[0009] The first asymmetric synthesis of Tetrodotoxin was reported by Isobe et al. in January 2003 (Isobe,M. et al, J.
Am. Chem. Soc, 2003, 125, 8798-8805). This synthesis relied in a Claissen rearrangement, a Shonogashira coupling
and an intramolecular carbamate-ester conjugate addition as key steps. After 67 steps Tetrodotoxin was obtained in a
1,22% overall yield.
[0010] Shortly after (June, 2003) Dubois et al. reported a second asymmetric synthesis of Tetrodotoxin having a
Rhodium-catalazed carbene and nitrene insertion as key step with an overall yield of 0.49% after 32 steps (Du Bois, J-;
Hinman, A. J. Am. Chem. Soc. 2003, 125, 11510-11511).
[0011] Recently, Isobe et al, have reported an additional asymmetric total synthesis comprising 62 steps and an overall
yield of approximately 1% from a vinilic methyl intermediate (Isobe, M.; Urabe, D.; Nishikawa, T. Angew. Chem. Int. Ed.
2004, 43, 4782-4785).
[0012] Also, Isobe has reported the synthesis of different unnatural analogues of Tetrodotoxin following similar strat-
egies as those reported for Tetrodotoxin. Concretely, Isobe et al, has reported the synthesis of (-)-5,11-Dideoxytetro-
dotoxin (Isobe, M.; Asai, M.; Ohyabu, N.; Yamamoto, N.; Nishikawa, T. Angew. Chem. Int. Ed. 1999, 38, 3081-3084),
(-)-8,11-Dideoxytetrodotoxin (Isobe, M.; Asai, M.; Iwabuchi, T.; Yoshida, K.; Urabe, D., Nishikawa, T. Org. Lett. 2002,
16, 2679-2682; Isobe, M.; Asai, M.; Iwabuchi, T.; Yoshida, K.; Urabe, D.; Nishikawa, T. Chem. Eur. J. 2004, 10, 452-462)
and 11-Deoxytetrodotoxin (Isobe, M.; Asai, Nishikawa, T. J. Am. Chem- Soc. 2002, 124, 7847-7852).
[0013] Finally, Sato et al. have recently reported an asymmetric total synthesis of Tetrodotoxin from myo-inositol in
approximately 0.14% overall yield after 40 steps (Sato, K.; Akai, S.; Sugita, N.; Ohsawa, T.; Kogure, T.; Shoji, H.;
Yoshimura, J. J. Org. Chem. 2005, 70, 7496-7504).
[0014] Also, further discussions regarding different synthetic approaches to Tetrodotoxin and its analogues may be
reviewed in Koert, U. T. Angew. Chem. Int. Ed. 2004, 43, 5572-55769.
[0015] In view of all of the above there is an existing need of providing an alternative cost effective and efficient
synthesis of Tetradotoxin and analogues thereof, which can be used for the industrial production of sufficient amounts
of these compounds. Further, it will open the way to new analogues with useful biological and pharmacological properties.
[0016] As a general trend, all the above mentioned synthesis start with the construction of a highly functionalized
cyclohexane, which is used as the template over which, first, the ortocsther (or an immediate precursor such as a lactone)
and, then, the six-membered ring having the guanidine residue, are built (Figure I). Due to the high polarity of the
orthoester and the guanidine group, their introduction in the molecule is usually delayed until the last steps of the synthesis.
SUMMARY OF THE INVENTION
[0017] It has know been surprisingly found that the compounds described in our applications EP 04076477.1 and
PCT/EP2005/005149, which are herein incorporated by reference in their entirety, are suitable precursors for the syn-
thesis of Tetrodotoxin and analogues thereof. These compounds, having the following formula:
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wherein R1, R2, R3 and R4 are each independently selected from H, OH, halo, OPr, -O, cyano, substituted or unsubstituted
alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted aryloxy, substituted or unsubstituted amino or halogen,
R5 and R6 together are =O or -O-(CH2)m-, wherein m is selected from 1, 2, 3, 4 or 5;
or R5 is selected from H, OH, OPr and R6, is selected from hydrogen, cyano, substituted or unsubstituted alkyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl, substituted or un-
substituted aryl, substituted or unsubstituted heterocyclyl,
with the proviso that at least one of R1, R2, R3, R4 or R5 is OH, substituted or unsubstituted alkoxy, substituted or
unsubstituted aryloxy or OPr;
Pr is an hydroxyl protecting group that can be the same or different on each of R1, R2, R3, R4 or R5 and that can
simultaneously protect 1, 2 or 3 hydroxy groups;
the dotted line represents a single or double bond, with the proviso that when both R1 and R2 or R3 and R4 are H then
there is a double bond between the two C to which the H are linked;
Z is -(CRaRb)n- or -CH2-(CRaRb)- or -(CRaRb)-CH2- or -CH2-(CRaRb)-CH2-, or - (CH2)2-(CRaRb)- or -(CRaRb)-(CH2)2-
wherein n is a number selected from 1, 2 or 3 and Ra and Rb are each independently selected from hydrogen, substituted
or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or un-
substituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubsti-
tuted aryloxy, substituted or unsubstituted amino or halogen;
Y is selected from -O-, -S-, -NRa- or -C(O)-, wherein Ra is as previously defined;
W is a group comprising at least a group selected from substituted or unsubstituted aryl, substituted or usubstituted
heterocyclyl, substituted or unsubstituted alkenyl;
or a salt, complex or solvate thereof;
already include in their structure the quaternary C8a of TTX or analogues thereof
[0018] Further, in contradiction to previously disclosed synthesis of TTX and analogues thereof (see Figure I), by
incorporation of a guanidine (or similar) residue to a compound of formula IIa it is possible to easily form the guanidine
ring prior to the formation of the orthoester (Figure II):
[0019] Surprisingly, through this novel strategy TTX and analogues thereof are obtained in overall good yield, in fewer
steps and using cheap and readily available materials. Therefore, an aspect of the present invention is a process for
the synthesis of a compound of formula 1:
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wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R5 is selected from H, OH, OPr;
R6 and R7 together are -O or =NPm; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R10 is selected from H, OH, OPr or =O;
R11 is H, Pr or a negative charge;
R12 is H or Prn;
X1 is selected from NPm, NH, O or S;
X2 is selected from NPm, NH, ⊕NH2, O or S;
Ra and Rb are each independently selected from H, OH, OPr or substituted or unsubstituted alkyl, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
or its salts or tautomers,
comprising the step of forming a orthoester from a compound of formula VII:
wherein
R1 and R2 together are -O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl, substituted or un-
substituted aryl, substituted or unsubstituted heterocyclyl;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together are -O-,
forming and epoxide ring;
R12 is H or Prn;
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Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or unsub-
stituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino
or halogen;
Pr is a hydroxyl protecting group;
Pm is a amino protecting group;
X1 is selected from NPm, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S.
[0020] A further aspect of the present invention is a process for the synthesis of a compound of formula VII
wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl, substituted or un-
substituted aryl, substituted or unsubstituted heterocyclyl;
R6 and R7 together are -O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
R9 and R10 are each independently selected from 1-1, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together are -O-,
forming and epoxide ring;
R12 is H or Prn;
Ra and Rb are each independently selected from 11, OH, OPr, substituted or unsubstituted alkyl, substituted or unsub-
stituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino
or halogen;
Pr is a hydroxyl protecting group;
Pm is a amino protecting group;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S;
which comprises opening the 1-aza-2-oxaspiro ring of a compound of formula VI
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wherein X1, X2, R1, R2, R3, R5, R6, R7 R9, R10, Ra and Rb have the same meaning as in formula VII.
[0021] A further aspect of the present invention is a process for the synthesis of a compound of formula I:
wherein
R1 and R2 together arc -O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R5 is selected from H, OH, OPr;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R10 is selected from H, OH, OPr or = O;
R11 is H, Pr or a negative charge;
R12 is H or Prn;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPm, NH, (NH2, O or S;
Ra and Rb are each independently selected from H, OH, OPr or substituted or unsubstituted alkyl, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
or its salts or tautomers,
comprising the following steps:
a) deprotecting the N-oxide residue of a compound of formula II
EP 1 785 427 A1
8
5
10
15
20
25
30
35
40
45
50
55
wherein
R3 and R9 are each independently selected from H, OH, OPr or =O;
R4 is selected from cyano, substituted or unsubstituted alkyl, OPr, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkinyl;
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R4 and R5 together are =O;
or R3 and R5 or R3 and R2 together are -O-, forming and epoxide ring;
W is a group comprising at least a group selected from substituted alkyl, substituted or unsubstituted aryl, substituted
or usubstitutcd heterocyclyl, substituted or unsubstituted alkenyl;
R1, R2, R10, Ra, Rb and Pr have the same meaning as in Formula I;
followed by the introduction of a residue of formula III
wherein
X1 is selected from NHPrn, NH2, N(Prn)2, wherein Prn can be the same or different,
OH, OPr, SH or SPrs;
X2 is selected from NPrn, NH, O or S;
Prs is a sulfur protecting group;
Pr and Prn have the same meaning as in formula 1;
to give a compound of formula IV
wherein
R1, R2, R3, R4, R5, R9, R10, Ra and Rb have the same meaning as in formula II;
X1 and X2 have the same meaning as in formula III;
b) closing the ring between X1 and either R4 or C4a of the compound of formula IV to give a compound of formula V
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wherein
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S;
R1, R2, R3. R5, R9, R10, Ra and Rb have the same meaning as in formula II;
R6 and R7 have the same meaning as in formula I;
c) if necessary, subjecting the compound of formula V to a rearrangement to give a compound of formula VI
wherein
R1, R2, R3, R5, R6, R7, R9, R10, X1, X2, Ra and Rb have the same meaning as in formula V;
d) opening the 1-aza-2-oxaspiro residue of the compound of formula VI to give a compound of formula VII.
wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl,
substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
EP 1 785 427 A1
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R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together arc -O-,
forming and epoxide ring;
R12 is H or Prn;
Ra and Rb are each independently selected from 11, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or un-
substituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPm, NH, (NH2, O or S; and
e) formation of the orthoester to give a compound of formula I from a compound of formula VII.
[0022] It is to be understood that each one of the steps a) to e) as defined in the method above are in themselves
also an aspect of the invention.
[0023] According to one embodiment of the invention, the formation of the compound of formula 1 is carried out in
two steps wherein
d1) the compound of formula VII is treated with acid to give a compound of formula Villa
wherein
R1, R2, R3, R5, R6, R7, R10, R12, X1, X2, Ra, Rb, Pr and Prn have the same meaning as in formula VII, if R9 is OH
or OPr; or
d2) the compound of formula VII is treated with acid to give a compound of formula VIIIb
wherein
R1, R2, R5, R6, R7, R9, R10, R12 X1, X2, Ra, Rb, Pr and Pm have the same meaning as in formula VII if R3 is OH or OPr.
[0024] Further aspects of the invention are to provide compounds of formula IV, V, VI and VII as defined above.
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[0025] A further aspect of the invention is directed to the use of a compound of formula II as defined above, or of a
compound as defined in claim 1 of patent application PCT/EP2005/005149, in the synthesis of Tetrodotoxin or analogues
thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0026] In studying the structure of compounds obtained in our previous patent applications (EP 04076477.1 and
PCT/EP2005/005149) it was realized that the quaternary centre at carbon 8a of TTX had been built. Taking advantage
of this it has now been devised the synthesis of TTX and analogues thereof.
[0027] In our copending application PCT/FP2005/005146 we described a process for producing a spirolactam com-
pound having the following formula 4
wherein R1 to R4 are independently selected from H, halogen, protected or unprotected hydroxy, protected or unprotected
silyloxy, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkoxy or aryloxy, substituted or
unsubstituted aryl, substituted or unsubstituted heterocyclyl, nitro, substituted or unsubstituted amino, mercapto, sub-
stituted or unsubstituted arylthio or alkylthio;
Z is -(CRaRb)n- or -CH2-(CRaRb)- or -(CRaRb)-CH2- or -CH2-(CRaRb)-CH2-, or - (CH2)2-(CRaRb)- or -(CRaRb)-(CH2)2-
wherein n is a number selected from 1, 2, 3 and Ra and Rb are each independently selected from hydrogen, substituted
or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or un-
substituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubsti-
tuted aryloxy, substituted or unsubstituted amino, or halogen;
Y is selected from -O-, -S-, -NRa- or -C(O)-, wherein Ra is as previously defined; and
W is a group with sufficient electronic density to stabilize the compound through π (pi) interactions with the benzodienone
moiety such as a group selected from substituted or unsubstituted arylalkyl, substituted or usubstituted heterocyclylalkyl,
substituted or unsubstituted alkenyl;
comprising the steps of reacting a compound of formula 3
wherein R5 is hydrogen or susbtituted or unsubstituted alkyl and Hal is F, Cl, Br, 1 or -SO2CF3;
with an N-acylnitrenium ion forming agent such as a silver salt to produce the spirolactam compound.
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The compound of formula 3 is prepared by reacting a Weinreb-type amide compound of formula:
with a a halogenating agent; preferably an agent selected from alkyl hypochlorite, alkyl hypobromite, sodium bromite,
sodium hypochlorite, benzyltrimethylammonium trihalide, N-halosuccinimide, N-halophthalimide, or phenyliodine (III)
bis(trifluoroacetate) (PIFA).
[0028] The process to obtain the starting materials (compounds of formula II) of the present invention arc described
in our copending application PCT/EP2005/005149, and involve starting from a compound of formula 4 above and then
applying a basic set of reactions selected from:
a) Hydroxilation dihydroxylation or ketohydroxylation: using mild (such as OsO4/ N oxide amine) or strong systems
(such as RuCl3) depending on the position to be hydroxylated. Alternative systems are also envisaged.
b) Nucleophilic attack at the carbonyl group: for example with a carbanion on a sp, sp2 or sp3 C, the carbanion can
be prepared or generated in situ; or with an hydride. The Nucleophilic attack allows the introduction of new func-
tionalities, new carbonated structures and also epoxides or double bonds, depending on the reagents used.
c) Hydroxyl inversion : for example through epimerization or inversion, for example in Mitsunobu conditions.
d) Hydroxyl or carbonyl protection: using the same or different protecting groups in conditions as explained above.
e) Allylic rearrangements: allows migration of a double bond.
[0029] Although each of these procedures are well known and the appropriate reagents can be selected by the person
skilled in the art of organic synthesis, their application to our structures gives new compounds and unexpected results
in terms of reactivity and selectivity.
[0030] Thus the different intermediate compounds of the invention and the starting materials can be prepared using
a basic set of simple reactions that allow the protection, functionalisation of the different positions in a very stereospecific
manner. These procedures will be explained below. Throughout the description and claims the configurations given arc
only relative configurations. Enantiomeric compounds of those described may be prepared using starting materials or
reagents when needed which have the opposite optical rotation.
[0031] The starting materials for the processes of the present invention are the compounds of formula II. As mentioned
before, synthetic approaches to these compounds are disclosed in our PCT/EP2005/005149 and PGT/EP2005/005146
which are incorporated herein by reference in their entirety. The compounds of formula II can be readily prepared with
the desired configuration and functionality, from commercial starting materials, and using a basic set of reactions.
[0032] Compounds of formula II are excellent starting materials for the synthesis of TTX derivatives. As shown in our
previous patent application, compounds of formula II with different patterns of substitution may be readily prepared. This
versatility allows the preparation of different analogues of TTX following the same basic steps as disclosed in the present
patent application.
[0033] According to one embodiment, compounds of formula II are compounds of formula IIa:
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wherein R1, R2, R3, Ra, Rb, W and Pr have the same meaning as in formula II.
[0034] According to a further embodiment, compounds of formula II are compounds of formula IIb:
wherein R1, R2, R3, Ra, Rb, W and Pr have the same meaning as in formula II.
[0035] According to a further embodiment, compounds of formula II arc compounds of formula IIe:
wherein R1, R2, R3, Ra, Rb, W and Pr have the same meaning as in formula II.
[0036] According to a further embodiment, compounds of formula II arc compounds of formula IId
wherein R1, R2, R3, Ra, Rb, W and Pr have the same meaning as in formula II.
[0037] According to a further embodiment, compounds of formula II are compounds of formula IIe
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wherein R1, R2, R3, Ra, Rb, W and Pr have the same meaning as in formula a II.
[0038] A compound of formula IIa-IId may itself be transformed in a different compound of formula IIa-IId. For example,
compounds of formula IIc can easily be transformed into compounds of formula IIa or IIb.
[0039] The reaction conditions for the above mentioned reactions are known to the skilled person. Triflation is a
standard reaction which may be performed, for example, following conditions described in Tetrahedron Lett. 1984, 25,
595-598. Introduction of a cyano group may be performed by nucleophilic substitution following, for example, the con-
ditions described in Can. J. Chem. 1993, 71, 1867-1872.
[0040] Having already the quaternary centre at C8a, there are many routes which can give a compound of formula
IV by removing the residue W and incorporating a residue of formula III. W can be considered an O protecting group,
and therefore any procedures adequate to remove protecting groups of the nature of W can be used. For example, for
a compound of formula IIc, wherein W is a benzyl group the following sequence yields the desired compound of formula IV:
[0041] Different kind of reagents can be used to introduce the group of formula III. For example thioureas, carbodiimides,
isocyanates or thioisocyanates can be used. Other alternatives will be apparent to the person skilled in the art.
[0042] Alternatively, it is also possible to prepare a compound of formula IV, using the methodologies described in
the two mentioned patent applications, wherein the W group is in fact a group of formula III. In other words, the group
of formula III can be introduced as early in the synthesis as desired, saving in some cases one step in the synthesis,
[0043] The residue of formula III may incorporate the guanidine residue of TTX and analogues thereof (positions 1,
2 and 3). In a preferred embodiment according to the present invention, X1 is selected from N(Prn)2, wherein Prn groups
can be the same or different, NH or NHPrn, and X2 is NPm.
[0044] Compounds of formula IV already have the atoms necessary to build the basic skeleton of TTX and analogues
thereof. According to one embodiment, compounds of formula IV are compounds of formula IVa
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wherein R1, R2, R6, R7, Ra, Rb, X1, X2 and OPr are as defined in formula IV.
[0045] According to one embodiment, compounds of formula IV arc compounds of formula IVb
wherein R1, R2, R6, R7, Ra, Rb, X1, X2 and OPr are as defined in formula IV.
[0046] According to another embodiment, compounds of formula IV are compounds of formula IVc
wherein R1, R2, R6, R7, Ra, Rb, X1, X2 and OPr are as defined in formula IV.
[0047] According to another embodiment, compounds of formula IV are compounds of formula IVd
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wherein R1, R2, R6, R7, Ra, Rb, X1, X2 and OPr are as defined in formula IV.
[0048] According to another embodiment, compounds of formula IV are compounds of formula IVe
wherein R1, R2, R6, R7, Ra, Rb, X1, X2 and OPr are as defined in formula IV.
[0049] In the same way as for compounds of formula II, the compound of formula IVa-IVd may itself be transformed
in a different compound of formula IVa-IVd. A particular example is shown below
[0050] The ring closure of the guanidine ring is performed through simple reactions depending on the compounds of
formula II selected as precursors. For example, where R4 is CN (compounds according to formula IVa or lVb) and X1
is N(Prn)2, wherein Prn is the same or different, NH2 or NHPrn, acid treatment yields the desired compound of formula
V through a rearrangement of the rings to give the more stable 2-iminotetrahydropirimidin-4(1H)-one. For example:
[0051] Examples of acids which can be used, are triflic acid, HCl, sulphuric acid, etc.
[0052] However, it is also possible to perform the stepwise synthesis of compounds of formula VI by mild acid treatment
of compounds of formula IV, isolating the resulting compounds of formula V having a 7-imino-1,2,6-oxadiazepan-5-one
ring, which are further treated under stronger acid conditions or heat to give compounds of formula VI.
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[0053] In the case of compounds IVd and IVe ring closure is achieved under different conditions and C4 is provided
by X1. Treatment of a compound of formula IVd or IVc with a strong base such as LDA or LiHMS, forms an anion which
attacks the cpoxidc or the carbonate.
[0054] In a variant of the invention a precursor of the group of formula III can be first linked to the position 4a or 4 and
then to the N of the lactame ring.
[0055] In a further variant of the invention the N-hydroxy moiety of compounds of formula II may be completely
deprotected under reductive conditions to the lactam and the precursor of the group of formula III linked directly to the
nitrogen of the lactam.
[0056] In a further variant of the invention the nitrogen in position 1 of the spirolactam may be protected as a hydrazine
group
wherein, preferably, R’ and R" are each indepently selected from hydrogen, substituted or unsubstituted alkyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsub-
stituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubsti-
tuted amino or halogen. The N-N bond is removed afterwards under reductive conditions.
[0057] It has also been observed that treatment of a compound of formula IV under acidic conditions, when R2 is OH
or OPr and R4 is cyano, both being in relative cis position, it is possible to obtain the lactone
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which itself undergoes ring closure to give a compound of formula V or VI.
[0058] From the compound of formula VI, further ring opening of the 1-aza-2-oxaspiro residue and protection of the
nitrogen in position 1 can be readily carried out. In a preferred embodiment according to the present invention, said ring
opening is performed via catalytic hydrogenation.
[0059] Compounds of formula VII are ready for orthoester bridge closure, which may be performed via a stepwise
sequence, first forming a lactone and then the orthoester, or by direct formation of the orthoester in a single step.
[0060] Conditionsunder which orthoester ring closure has been performed arcknown to theskilled personand generally
involve acid treatment. According to one embodiment of the present invention, a compound of formula VII wherein R3,
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R8 and R9 are OH is treated acid treatment, preferably HCl, fellowed by peracetylation. The resulting acetylated compound
is treated with hydride, followed by triethylamine in water-methanol, to give TTX (see Isobe, M.; Urabe, D.; Nishikawa,
T. Angew. Chem. Int. Ed. 2004, 43, 4782-4785). In a further embodiment, persylilation me be carried out instead of
peracetylation.
[0061] In a preferred embodiment, R3 and R9 are OPr, wherein OPr is a silyl protecting group, and R8 is OH. This
compounds achieve deprotection and formation of the orthoester in a single step by treatment with acid, preferably HCl.
[0062] Further, this protection strategy is specially useful when other hydroxyl groups in the molecule are protected
with benzoate, since both, being different protecting groups, are removed under the same conditions in one step.
[0063] In a further embodiment, compounds of formula VII wherein R3 and R5 together are -O-, forming and epoxide
ring, are also treated under acidic conditions followed by persylilation or peracetylation. As in the previous embodiment,
although the reaction may be carried out in three steps (deprotection, acid treatment, persylilation or peracetylation),
an adequate selection of protecting groups yields TTX or an analogue thereof in two steps.
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[0064] There are a number of reactions which have been performed in different stages of the synthesis. One example
is protection and deprotection reactions which have been performed following known conditions to the skilled person.
Examples of protecting groups can be found in reference books such as Greene and Wuts’ "Protective Groups in Organic
Synthesis", John Wiley & Sons, Inc., New York, 1999. Adequate protection strategies can be selected on the different
hydroxy or amino groups in order to simplify and control the different steps of the processes.
[0065] Also, hydrogenation, when necessary, of the C5-C4a bond has been performed in compounds of formula IV,
V, VI, VII or VIIIa. The election of the most suitable stage for hydronegation depends mainly on the protecting groups
present in the molecule.
[0066] As disclosed in the previous scheme, hydrogenation usually takes place from the less hindered face. For
example, in the case of a compound of formula IVa, catalytic hydrogenation proceeds with almost complete stereose-
lectivity when R3, R9 and R10 are OPr. We believe this is due to steric hinderance between R9 and Ra and Rb.
[0067] On the other hand, in some sequences it has been necessary to perform the opposite reaction and introduce
a double bond between C4a and C5. This can he readily achieved from a compound of formula V, VI, VII or VIIIa, wherein
R3 is OH, by oxidation to form the ketone in C5, and subsequent enolization-protection.
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[0068] Having a double bond between C4a and C5 an epoxide ring has been introduced through conventional con-
ditions in compounds of formula 11, IV, V, VI and VII.
[0069] Also, if it is necessary to introduce the hydroxyl group at C9, hydroxylation α to a carbonyl group is readily
achieved using conditions known to the skilled person. For example, formation of the corresponding enolate followed
by addition of oxaziridine to a compound of formula II-VIII results is the introduction of the hydroxyl group (see J.Org.Chem.
1992, 57,6387-6389). The hydroxyl group can then be protected with any desired hydroxyl protecting group. This reaction
can also be performed at different stages of the synthesis. Further, compounds of formula II may already comprise the
hydroxyl group (or a suitable precursor) at C9.
[0070] When the previous hydroxylation at C9 arc carried out, two isomers are possible, and the one corresponding
to the less hindered face of the molecule is obtained in greater yield. If the hydroxyl with the desired configuration at C9
is obtained, protection can in some cases be necessary in order to avoid the formation of 4-dehydroxy by-products.
[0071] In other cases, the TTX derivative with the opposite configuration at C9 can be obtained as the mayor product.
This derivatives are also useful because they do not form the 4-dehydroxy by-products above mentioned.
[0072] However, epimerization of different hydroxyl functional groups, including at C9, throughout the synthesis can
be carried out under Mitsonobu conditions (Mitsunobu, 0-; Synthesis, 1, 1981)
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[0073] In our previous patent applications EP 04076477.1 and PCT/EP2005/005149 we devised different reaction
sequences in order to arrive to the correct structure of R1 and R2. The same reaction sequences can also be successfully
applied to compounds of formula 1-VIIIb. For example, introduction of C11 in a compound of formula VI having ketone
at C6 can be performed in three different ways
[0074] In some reaction sequences it is necessary to remove R5 (for example, wherein R5 is OPr) in order to arrive
to the correct structure of TTX. This can be done in compounds of formula 1, 11, IV, V, VI, VII or VIII by treatment with
a base. For example, an -OTMS on C4a in a compound of formula I is readily removed by treatment with NaHMDS.
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[0075] According to one embodiment, compounds of formula V are compounds of formula Va
wherein R1, R5, R6, R7, Ra, Rb, Pr, X1 and X2 are as defined in formula V.
[0076] According to a further embodiment, compounds of formula VI are compounds of formula VIa
wherein R1, R5, R6, R7, Ra, Rb, Pr, X1 and X2 are as defined in formula VI.
[0077] According to a further embodiment, compounds of formula VII are compounds of formula VIIa
wherein R1, R5, R6, R7, R12; Ra, Rb, Pr, X1 and X2 are as defined in formula VII.
[0078] From the above, it is evident to the skilled person the synthesis of different analogues of TTX. For example,
the analogues described by Sato (scc figure 1, page 7497 in Sato, K.; Akai, S.; Sugita, N.; Ohsawa, T.; Kogure, T.;
Shoji, H.; Yoshimura, J. J. Org. Chem, 2005, 70, 7496-7504) are readily prepared following the synthesis disclosed in
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the present patent application starting from a suitable compound of formula II. For example, 8, 11-dideoxy TTX is readily
available from a compound of formula II, IV, V, VI, VII, Vllla or VIIIa wherein R1, is a methyl group and R10 is hydrogen.
Also new useful analogues which have not been described so far, can also be prepared using the structures and set of
reactions of the present invention. Different nor or deoxy -derivatives are obtained by putting into practice the teaching
of the present invention. One example is 4-nor TTX, which be obtained from a compound of formula IVc.
[0079] Further embodiments of the compounds of the invention are described below and in the examples. It is evident
for the skilled person that many variations and configurations arc possible and can be obtained at will depending on the
compounds selected as starting materials, the relative configurations of the functional groups present, the presence or
not of chiral centers, and on the combination of reactions that are applied. The present invention encompasses all such
variations and possibilities.
[0080] In the above definition of compounds of formula I-VIIIb and in the description the following terms have the
meaning indicated:
"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms, containing
no saturation, having 1-12, preferably one to eight carbon atoms, and which is attached to the rest of the molecule
by a single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc. Alkyl radicals may be optionally
substituted by one or more substituents such as halo, hydroxy, alkoxy, OPr, OBn, OBz, carboxy, cyano, carbonyl,
acyl, alkoxycarbonyl, amino, imino, nitro, mercapto and alkylthio.
"Alkoxy" refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above, e. g-, methoxy, ethoxy,
propoxy, etc. "Aryloxy" refers to a radical of formula -ORb wherein Rb is an aryl radical as defined below. "Amino"
refers to a radical of the formula-NH2, -NHRa, -NRaRb.
"Aryl" refers to an aromatic hydrocarbon radical such as phenyl, naphthyl or anthracyl. The aryl radical may be
optionally substituted by one or more substituents such as hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl,
nitro, cyano, dialkylamino, aminoalkyl, acyl and alkoxycarbonyl, as defined herein.
"Aralkyl" refers to an aryl group linked to an alkyl group such as benzyl and phenethyl.
"Cycloalkyl" refers to a saturated carbocyclic ring having from 3 to 8 carbon atoms.
"Heterocyclyl" refers to a stable 3- to 15- membered ring which consists of carbon atoms and from one to five
heteroatoms selected from the group consisting of nitrogen, oxygen, and sulphur, preferably a 4-to 8-membered
ring with one or more heteroatoms, more preferably a 5-or 6-membered ring with one or more heteroatoms. For the
purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic ring system, which may include
fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidised;
the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated or
aromatic. Examples of such heterocycles include, but arc not limited to, azepines, benzimidaxole, benzothiazole,
furan, isothiazole, imidazole, indolc, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran.
"Hydroxyl protecting group" refers to a group that blocks the OH function for further reactions and can be removed
under controlled conditions. The hydroxyl protecting groups are well known in the art, representative protecting
groups are silyl ethers such as trimethylsilyl ether, triethylsilyl ether, tert-butyldimethylsilyl ether, tert-butyldiphenylsilyl
ether, tri-isopropylsilyl ether, diethylisopropylsilyl ether, thexyldimethylsilyl ether, triphenylsilyl ether, di-tert-butyl-
methylsilyl ether; alkyl ethers such as methyl ether, tert-butyl ether, benzyl ether, p-methoxybenzyl ether , 3,4-
dimethoxybenzyl ether, trityl ether; allyl ether; alkoxymethyl ether such as methoxymethyl ether, 2-methox-
yethoxymethyl ether, benzyloxymethyl ether, p-methoxybenzyloxymethyl ether, 2-(trimethylsilyl)ethoxymethyl ether;
tetrahydropyranyl and related ethers; methylthiomethyl ether; Esters such as acetate ester, benzoate ester; pivalate
ester; methoxyacetate ester; chloroacetate ester; levulinate ester; Carbonates such as benzyl carbonate, p-nitroben-
zyl carbonate, tert-butyl carbonate, 2,2,2-trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, allyl carbonate;
and sulphates such as SO3py. In some cases activating groups such as triflatc are also included as protecting
groups. Additional examples of hydroxyl protecting groups can be found in reference books such as Greene and
Wuts’ "Protective Groups in Organic Synthesis", John Wilcy & Sons, Inc., New York, 1999.
"Amino protecting group" refers to a group that blocks the NH2 function for further reactions and can be removed
under controlled conditions. The amino protecting groups are well known in the art, representative protecting groups
are carbamates and amides such as substituted or unsubstituted or substituted acetates. Also different alkyl moeties
may serve as amino protecting groups. Said alkyl groups may optionally be substituted by one or more substituents
such as halo, hydroxy, alkoxy, alkyloxymethyl ethers, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro,
mercapto and alkylthio. Additional examples of amino protecting groups can be found in reference books such as
Greene and Wuts’ "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999.
"Sulfur protecting group" refers to a group that blocks the SH function for further reactions and can be removed
under controlled conditions. Examples of sulfur protecting groups can be found in reference books such as Greene
and Wuts’ "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999.
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[0081] References herein to substituted groups in the compounds of the present invention refer to the specified moiety
that may be substituted at one or more available positions by one or more suitable groups, e. g., halogen such as fluoro,
chloro, bromo and iodo ; cyano; hydroxyl ; nitro ; azido ; alkanoyl such as a C1-6 alkanoyl group such as acyl and the
like ; carboxamido ; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon
atoms and more preferably 1-3 carbon atoms ; alkenyl and alkynyl groups including groups having one or more unsatu-
rated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms ; alkoxy groups having one or more
oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms ; aryloxy such as phenoxy ; alkylthio
groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms or from 1
to about 6 carbon atoms ; alkylsulfinyl groups including those moieties having one or more suliinyl linkages and from 1
to about 12 carbon atoms or from 1 to about 6 carbon atoms ; alkylsulfonyl groups including those moieties having one
or more sulfonyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ; aminoalkyl groups
such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ;
carbocylic aryl having 6 or more carbons, particularly phenyl or naphthyl and aralkyl such as benzyl. Unless otherwise
indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each
substitution is independent of the other.
[0082] In the preparation of compounds wherein R9 and R10 are both protected hydroxyl groups, the two hydroxyl
groups can be protected with two different protecting groups, first protecting the position C7 and then the position C8.
[0083] To introduce protecting groups standard procedures can be used, such as those described in Greene and
Wuts’ "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999 or Kocienski, P.J. "Protecting
Groups", 3rd Ed.Thieme Chemistry, 2003.
[0084] The presence of vicinal hydroxyl groups allows the simultaneous protection of two of them through the use of
diol protecting groups if desired. Among the diol protecting groups that can be used we have O,O-acetals such as
isopropylidene acetals (acetonides); cyclohexylidene and cyclopentylidene acetals; arylmethylene acetals; methylene
acetals; diphenylmethylene acetals; 1,2-diacetals such as dispiroketal (dispoke) derivatives, cyclohexane-1,2-diacetals,
butane-2,3-diacetals; silylene derivatives; 1,1,3,3-tetraisopropyldisiloxanylidene derivatives or N,O-acetals. Additional
examples of diol protecting groups can be found in reference books such as Greene and Wuts’ "Protective Groups in
Organic Synthesis", John Wiley & Sons, Inc., New York, 1999. Additionally, borolanes can be formed on the two vicinal
hydroxy groups, for example using phenylboric acid.
[0085] One example of such a compound with vicinal protection is :
[0086] In this case the 7 member ring accommodates the axial-equatorial position of the two OH being protected.
[0087] As an alternative, dihydroxylation and protection can be carried out simultaneously:
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Or, if desired, only one of the hydroxy groups can be selectively protected due to their different nature (primary versus
tertiary alcohol):
[0088] The use of protecting groups of a certain size, or that are linked simultaneously to two different positions can
therefore control the stereochemistry of the product.
[0089] Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ
only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures
except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-
enriched carbon or 15N-enriched nitrogen are within the scope of this invention.
[0090] The compounds of the invention may be in crystalline form either as free compounds or as solvates (e.g.
hydrates) and it is intended that both forms arc within the scope of the present invention. Methods of solvation are
generally known within the art.
[0091] The invention will be further illustrated by means of examples, which should not be interpreted as limiting the
scope of the claims.
EXAMPLES
General Methods and Materials.
[0092] All reactions described below were carried out under argon atmosphere unless otherwise noted. The solvents
used were distilled and dried under argon atmosphere before use. All starting materials were purchased commercially
(Aldrich, Fluka and Merck) and used without further purification. Flash Chromatography was executed on columns loaded
with 230-400 mesh silica gel Merck. TLC was carried out on silica gel Merck (Kieselgel 60F-254).
[0093] Melting points (mp) were determined on a Reichert Microscopic Hot-Stage and arc uncorrected- 1H and 13C
NMR spectra were measured on a Varian Gemini-200 and a Varian Inova-300 spectrometer with (CH3)4Si as an internal
reference and CDCl3 as solvent unless otherwise noted. Both 1H and 13C NMR spectral data are reported in parts per
million (δ) relative to residual sign of the solvent (CDCl3, 7.26 ppm and 77.0 ppm for 1H and 13C NMR, respectively). 1H
and 13C NMR designations arc: s (singlete); s br. (broad singlete); d (doublete); t (triplete); q (quartete); m (multiplete).
Infrared (IR) spectra were record on a Perkin-Elmer FT-IR spectrometer. U V spectra were record on a Perkin-Elmer
402 spectrometer. Low-resolution mass (LRMS) spectra were obtained on a Hewlett Packard 5973 MSD spectrometer
with a direct inlet system (EI) at 70 eV. Microanalytical data (E.A.) were obtained on a Perkin-Elmer 240C and Heraus
CHN-O instruments at the Instrumental Analysis Department of lnstituto de Quimica Orgánica General (C.S.I.C.).
Example 1:
Preparation of rac-(4S,6S,7R,8S,9S)-1-Bencyloxy-7-benzoyloxymethyl-6-tert-butyldimethylsyliloxy-7,8,9-trihy-
droxy-8,9-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-diyl)-1-azaspiro[3.5]nonane-2,5-dione (70)
[0094]
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PCC (15 mg, 0,072 mmol, 1.5 eq.) was added to a solution of rac-(4R,5S,6S,7S,8R,9R)-1-benzyloxy-7-benzoyloxyme-
thyl-8-tert-butyldimethylsilyloxy-5,6,7,9-tetrahydroxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiror[3.5]
nonan-2-one (69) (39 mg, 0.048 mmol, 1.0 eq.) in CH2Cl2 (0,6 ml) and was stirred for 20 hours at room temperature.
After that time, a little amount of Celite was added and the solvent was eliminated under reduced pressure. The product
was purified by column chromatography (hexane/AcOEt, 10:1) and rac-(4S,6S,7R,8S,9S)-1-benzyloxy-7-benzoy-
loxymethyl- 6-tert-butyldimethylsilyloxy- 7,8,9- trihydroxy- 8,9-O-(1,1,3,3- tetraisopropyldisiloxane- 1,3- diyl)- 1- azaspiro
[3.5]nonane-2,5-dione (70) (36 mg. 92% yield) was obtained as a white solid, Also, the starting product 69 (2 mg, 5%)
and an isomer of 70 (1mg, 3% yield) was recovered as a white solid.
P.f.: 163-164˚C.
Rf= 0.53 (TLC, hexano/AcOEt, 3:1).
1H-NMR (200MHz, CDCl3): δ 8.03 (2H, dm, J = 6.9 Hz, Bz), 7.64 (1H, tm, J = 7.3 Hz, Bz), 7.49 (2H, ddm, J = 7.3, 6.9
Hz, Bz), 7.44-7.27 (5H, m, Ph), 5.17 (2H, s, OCH2Ph), 4.85 (1H, d, J = 4.2 Hz, H-9), 4.79 (1H, part A syst. AB, J = 11.7
Hz, H-10), 4,57 (1 H, dd, J = 4.2, 1.3 Hz, H-8), 4.56 (1H, part B syt. AB, J = 11.7 Hz, H-10’), 4.12 (1H, d, J = 1.3 Hz, H-
6), 3.47 (1H, part A syst. AB, J= 13.5 Hz, H-3), 2.95 (1H, s, OH), 2.69 (1H, part B syst. AB, J= 13.5 Hz, H-3’), 1.18-0.94
(28H, m, TIPDS), 0.88 (9H, s, C(CH3)3), 0.08 (3H, s, SiCH3), 0.04 (3H, s, SiCH3).
13C-NMR (75MHz, CDCl3): δ 203.1 (C-5), 167.3, 164.7, 135.6, 133.8, 129.7, 128.9, 128.6, 128.2, 78.6, 77.6 (C-6), 75.0
(C-7), 74.6 (C-8), 72.5 (C-4), 68.5 (C-9), 66.6, 39.9 (C-3), 25.6, 18.0, 17.7, 17.4, 17.35, 17.3, 17.2, 17.1, 17.0, 16.9,
13.9, 13.15, 13.1, 13.05, - 4.7, -5.6.
IR (film): ν 3398, 2947, 2889, 2862, 1763, 1725, 1602, 1588, 1461, 1411, 1385, 1322, 1266, 1150, 1119, 1067, 998,
950, 889, 872, 840, 778 cm-1.
LRMS (API-ES+): m/z 1650 (2M+Na)+, 836 (M+Na)1, 814 (M+H)+.
E.A. (C41H63NO10Si3): Found: C, 60.59; H, 7.86; N, 1.95. Calculated: C, 60.48; H, 7.80; N, 1.72.
Example 2:
Preparation of rac-(4S,6S,7R,8S,9S)-7-Benzoyloxymethyl-6-tert-butyldimethylsyliloxy-1,7,8,9-tetrahydroxy-
8,9-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-diyl)-1-azaspiro[3.5]nonane-2,5-dione (71)
[0095]
Pd/C (6mg, 10% w/w, 0,005 mmol, 0,06 eq.) was added to a solution of rac-(4S,6S,7R,8S,9S)-1-benzyloxy-7-benzoy-
loxymethyl- 6-tert-butyldimethylsilyloxy- 7,8,9- trihydroxy- 8,9-O-(1,1,3,3- tetraisopropyldisiloxane- 1,3- diyl)- 1- azaspiro
[3.5]nonane-2,5-dionc (70) 870 mg, 0,086 mmol, 1.0 eq.) in MeOH (2 ml) and the resultant suspension was stirred over
3 hours under hydrogen atmosphere. After that time, the mixture was filtered through Celite and the catalyst was washed
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with MeOH. After that, de solvent was eliminated under pressure to yield rac-(4S,6S,7R,8S,9S)-7-Benzoyloxymethyl-
6-tert-butyldimethylsilyloxy-1,7,8,9-tetrahydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]non-
ane-2,5-dione (71) (40 mg., 64% yield) as a white solid.
Rf = 0.22 (TLC, hexane/AcOEt, 3:1).
1H-NMR (300MHz, CDCl3): δ 8.06 (2H, dm, J = 7.1 Hz, Bz), 7.59 (111, tm, J = 7.3 Hz, Bz), 7.46 (211, dd, J = 7.3, 7.1
Hz, Bz), 4.87 (1H, d, J = 4.0 Hz, H-9), 4.76 (1H, part A syst. AB, J = 11.7 Hz, H-10), 4,59 (1 H, dd, J = 4.0, 1.0 Hz, H-
8), 4.51 (1H, part B syst. AB, J = 11.7 Hz, H-10’), 4.14 (1H, d, J = 1.0 Hz, H-6), 3.60 (1H, s ancho, HO-N), 3.47 (1H,
part A syst. AB, J = 13.5 Hz, H-3), 3.47 (1H, s, HO-C(7)), 2.69 (1H, part B syst. AB, J = 13.5 Hz, H-3’), 1.18-0.96 (28H,
m, TIPDS), 0.85 (9H, s, C(CH3)3), 0.04 (3H, s, SiCH3), -0.01 (3H, s, SiCH3).
13C-NMR (75MHz, CDCl3): δ 204.9, 167.2, 164.5, 133.7, 129.7, 129.0, 128.6, 77.4, 74.9, 74.3, 71.8, 68.3, 66.5, 39.7,
25.5, 18.0, 17.6, 17.5, 17.4, 17.2, 17.1, 17.0, 16.9, 13.9, 13.0, -4.8, -5.7.
LRMS (API-ES+): m/z 746 (M+Na)+, 724 (M+H)+.
Example 3:
Preparation of rac-(4S,6S,7R,8S,9S)-7-Benzoyloxymethyl-6-tert-butyldimethylsilyloxy-7,8,9-trihydroxy-1-(N,
N’-diisopropylcarbamimidoyloxy)-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]nonane-
2,5-dione (72)
[0096]
[0097] Diisopropylcarbodiimide (8 ml, 0,052 mmol, 1.0 eq.) was added at room temperature to a solution of rac-(4S,
6S,7R,8S,9S)-7-Benzoyloxymethyl-6-tert-butyldimethylsiloxy-1,7,8,9-tetrahydroxy-1-8,9-O-(1,1,3,3-tetraisopropyldisi-
loxane-1,3-diyl)-1-azaspiro[3.5]nonane-2,5-dione (71) (38 mg, 0,052 mmol, 1.0 eq.) in CH3CN (1 ml). After 36 hours,
more diisopropylcarbodiimide (1.0 eq.) was added and the resultant mixture was stirred over 5 hours at room temperature.
After that time, dc solvent was removed under reduced pressure and the residue was purified by column chromatography
(hexane/AcOEt, 10:1) obtaining rac-(4S,6S,7R,8S,9S)-7-Benzoyloxymethyl-6-tert-butyldimethylsilyloxy-7,8,9-trihy-
droxy-1-(N,N’-diisopropylcarbamimidoyloxy)-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]non.ine-
2,5-dione (72) (24 mg. 54% yield), as a white solid. Two by-products ((mg Rf- 0,59 (TLC, hexane/AcOEt, 3:1) and 7 mg
Rf = 0.36 (TLC, hexane/AcOEt, 3:1) and the starting hydroxyamida 71 (2 mtg., 5%) where also isolated.
P.f.: ˚C.
Rf= 0.69 (TLC, hexano/AcOEt, 3:1).
1H-RMN (300MHz, CDCl3): δ
13C-RMN (75MHz, CDCl3): δ
IR (film): ν cm-1,
LRMS (API-ES+): m/z
A.E. (C41H71N3O10Si3): Found: C,; H,; N,. Calculated: C, 57.92; H, 8.42; N, 4.94.
Example 4:
Preparation of rac-(4R, 5S, 6S, 7S, 8S, 9S)-1-Benzyloxi-7-benzoyloxymethyl-8,9-epoxi-5,6,7-trihydroxy-
5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5] nonan-2-one (61)
[0098]
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Tert-butyl hydroperoxide (86 ml, 80% weight solution in (t-BuO)2O, 0.689 mmol, 10.0 eq.) and molecular sieves 4Å were
added at room temperature to a solution of rac-(4R, 5S, 6S, 7R)-1-benzyloxi-7-benzoyloxymethyl-5,6,7-trihydroxy-5,6-O-
(1,1,3,3,tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3,5]non-8-en-2 one (41) (46 mg., 0.069 mmol, 1.0 eq.) in CH2Cl2
(0.6 ml). After 10 minutes, VO(acacc)2 (5mg, 0.021 mmol, 0,3 eq.) was added. The resultant mixture was stirred at room
temperature over 4 days. After that time, de mixture was diluted with CH2Cl2 (3 ml) and was filtered under reduced
pressure through Celite to eliminate the sieves. The solution was washed with an aqueous solution of NaHCO3 10% (2
ml), dried with anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure. The product was
purified by column chromatography (hexane/AcOEt, 4:1) and rac-(4R, 5S, 6S, 7S, 8S, 9S)-1-Benzyloxi-7-benzoyloxyme-
thyl-8,9-epoxi-5,6,7-trihydroxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]nonan-2-one (61) (41
mg, 87% yield) was obtained as a white solid.
Pyridine (2 ml, 0.024 mmol, 2.0 eq.), a catalytic amount of 4-dimethylaminopyridine (0.01 eq.) and benzoyl, chloride (2
ml, 0.014 mmol, 1.4 eq.) were sequentially added at 0˚C, to a solution of rac-(4R, 5S, 6S, 7S, 8S, 9S)-1-benzyloxi-8,9-
epoxi-5,6,7-trihydroxy-7-hydroxymethyl-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]nonan-2-one
(65) (87 mg, 0.012 mmol, 1.0 eq.) in CH2Cl2 (0.15 ml). After 18 hours at room temperature, more pyridine (2.0 eq.),
DMAP (0.01 eq.) and benzoyl chloride (1.4 eq,) at 0˚C were added, and the resulting mixture was stirred at room
temperature over 18 hours. After that time, the medium was neutralized by addition of saturated NaHCO3 and the mixture
was extracted with Et2O (3 x 2ml). The organic phase was washed with HCl 10% (2 ml) and NaCl saturated (2 ml), dried
with anhydrous MgSO4, filtered and the solvent eliminated under reduced pressure. The product was purified by column
chromatography (hexane/ Ac=Et, 6:1) obtaining rac-(4R, 5S, 6S, 7S, 8S, 9S)-1-Benzyloxi-7-benzoyloxymethyl-8,9-
epoxi-5,6,7-trihydroxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]nonan-2-one (61) 85 mg, 62%
yield) as a white solid.
Rf= 0.36 (TLC, hexane/AcOEt, 3:1); 0.51 (TI.C, hexanc/AcOEt, 2:1).
1H-NMR (200MHz, CDCl3): δ 8.07 (2H, dm, J = 7.0 Hz, Bz), 7.60 (1H, tm, J = 7.3 Hz, Bz), 7.53-7.41 (4H, m, Bz y Ph),
7.41-7.31 (3H, m, Ph), 5.12 (1H, part. A .syst. AB, J= 11.0 Hz, OCH2Ph), 5.03 (1H, part B syst. AB, J = 11.0 Hz, OCH2Ph),
4.58 (1H, part A. syst. AB, J = 12.0 Hz, H-10), 4.53 (1H, s broad, H-5), 4.52 (1H, part B syst. AB, J = 12.0 Hz, H-10’),
4.24 (1H, s broad, H-6), 3.52 (2H, s broad, H-8 y H-9), 3.16 (1H, part A syst. AB, J= 13.9 Hz, H-3), 2.81 (1 H, s, OH),
2.48 (1H, part B syst. AB, J = 13.9 Hz, H-3’), 1.13-0.98 (28H, m, TIPDS).
1H-NMR (300MHz, C6D6): δ 8.16 (2H, dm, J = 8.3 Hz, Bz), 7.50 (1H, d, J = 7.6 Hz, Bz), 7.20-7.01 (7H, m, Bz y Ph),
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5.10 (1H, part A syst. AB, J= 11.5 Hz, OCH2Ph), 5.06 (1H, part B syst. AB, J = 11.5 Hz, OCH2Ph), 4.76 (1H, t, J = 1.9
Hz, H-5 o H-6), 4.52 (1H, part A syst. AB, J= 11.7 Hz, H-10), 4.45 (1H, part B syst. AB, J = 11.7 Hz, H-10’), 4.28 (1H,
m, H-6 o H-5), 3.17 (1H, d, J = 13.7 Hz, H-3), 3.02 (1H, m, H-8 o H-9), 2.96 (1H, dd, J = 3.7, 1.9 Hz, H-9 o II-8), 2.73
(1H, m, OH), 2.18 (1H, dd, J= 13.7, 1.9 Hz, H-3’), 1.35-0.80 (28H, m, TIPDS).
1H-RMN (500MHz, CO(CD3)2): δ 8.12 (2H, m, Bz), 7.66 (1H, m, Bz), 7.57-7.46 (4H, m, Bz y Ph), 7.42-7.32 (3H, m, Ph),
5.12 (1H, part A syst. AB, J= 10.9 Hz, OCH2Ph), 5.06 (1H, part B syst. AB, J = 10.9 Hz, OCH2Ph), 4.98 (11-1, s, OH),
4.88 (1H, d, J - 2.4 Hz, H-5), 4.59 (1 H, part A syst. AB, J = 11.5 Hz, H-10), 4.54 (111, part B syst. AB, J = 11.5 Hz, H-
10’), 4.37 (1H, dd, J = 2.4, 1.3 Hz, H-6), 3.71(1H, d, J = 3.7 Hz, H-9), 3.64 (1 H, dd, J = 3.7, 1.3 Hz,H-8), 3,08 (1H, part
A syst. AB, J = 13.5 Hz, H-3), 2.68 (1H, part B syst. AB, J - 13.5 Hz, H-3’), 1.23-0.92 (28H, m, TIPDS).
13C-RMN (75MHz, CDCl3): δ 166.4, 163.9. 135.2, 133.4, 129.6, 129.5, 128.9, 128.7, 128.5, 128.4, 78.8, 76.6 (C-6),
71.4 (C-7), 66.8 (C-10), 66.2 (C-5), 65.5 (C-4), 60.3 (C-9), 55.0 (C-8), 38.3 (C-3), 17.6,17.5, 17.2, 17.1, 17.0, 16.9, 14.3,
14.2, 13.5, 13.2.
13C-RMN (125MHz, CO(CD3)2): δ 166.9, 164.4, 136.9, 134.2, 131.2, 130.5, 129.8, 129.5, 129.4, 129.3, 79.2, 78.5 (C-
6), 72.3 (C-7), 68.7 (C-10), 67.8 (C-5), 66.6 (C-4), 59.8 (C-9), 56.2 (C-8),38.8 (C-3), 18.2, 18.1, 17.7, 17.6, 17.55, 17.5,
15.4, 15.2, 14.4, 14.0.
IR (film): ν 3430, 2947, 2900, 2868, 1767, 1725, 1599, 1589, 1465, 1451, 1394, 1370, 1273, 1148, 1104, 1075, 1007,
941, 886, 823, 756, 711 cm-1.
LRMS (API-ES+): m/z 1389 (2M + Na)+, 706 (M+Na)+, 684 (M+H)1.
A.E. (C35H49NO9Si2). Hallado: C, 61.54; H, 7.37; N, 2.21. Calculado: C, 61.46; H, 7.22; N, 2.05.
Example 5:
Preparationofrac-(4R,5S,6S,7S,8S,9S)-7-benzoyloximethyl-8,9-epoxi-1,5,6,7-tetrahydroxi-5,6-O-(1,1,3,3-tetrai-
sopropyldiisosiloxano-1,3-diyl)-1-azaspiror[3.5]nonan-2-one (73)
[0099]
Over a solution of rac-(4R, 5S, 6S, 7S, 8S, 9S)-1-Benzyloxi-7-benzoyloxymethyl-8,9-epoxi-5,6,7-trihydroxy-
5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]nonan-2-one (61) (90 mg, 0.132 mmol, 1.0 eq.) in MeOH
(1.6 ml) Pd/C was added (8 mg, 10% wt, 0.008 mmol, 0.06 eq.) and the resulting suspension was stirred under hydrogen
for 3 hours, after which the mixture was filtrated through Celite and the catalyst washed with MeOH. Removal of the
solvent yielded rac-(4R,5S,6S,7S,8S,9S)-7-benzoyloximethyl-8,9-epoxi-1,5,6,7-tetrahydroxi-5,6-O-(1,1,3,3-tetraiso-
propyldiisosiloxane-1,3-diyl)-1-azaspiro[3.5]nonan-2-one (73) (78 mg, quantitative yield) as a white solid.
Rf = 0.08 (TLC, hexane/AcOEt, 2:1); 0.48 (TLC, hexane/AcOEt, 1:3); 0.20 (TLC, hexane/AcOEt, 1:1).
1H-NMR (200MHz, CDCl3): δ 8.07 (2H, d, J = 7.6 Hz, Bz), 7.60 (1H, t, J = 7.3 Hz, Bz), 7.46 (2H, dd, J = 7.6, 7.3 Hz,
Bz), 4.67 (1H, d, J = 1.7 Hz, H-5), 4.60 (1H, part A syst. AB, J = 12.1 Hz, H-10), 4.53 (1H, part B syst. AB, J = 12.1 Hz,
H-10’), 4.28 (1H, s broad, H-6), 3.60 (1H, d, J = 3.6 Hz, H-9), 3.49 (2H, s broad, H-8 y HO-N), 3.21 (1H, part A syst.
AB, J = 13.8 Hz, H-3), 2.87 (1H, s broad, HO-C(7)), 2.54 (1H, part B syst. AB, J = 13.8 Hz, H-3’), 1.15-0.95 (28H, m, TIPDS).
1H-NMR (500MHz, CO(CD3)2): δ 9.10 (1H, s broad, HO-N), 8.11 (2H, dm, J = 7.1 Hz, Bz), 7.66 (1H, tm, J = 7.5 Hz, Bz),
7.53 (2H, ddm, J = 7.5, 7.1 Hz, Bz), 4.83 (1H, s, HO-C(7)), 4.80 (1H, d, J = 2.4 Hz, 11-5), 4.57 (1H, part A syst. AB, J
= 11.5 Hz, H-1 0), 4-53 (1H, part B syst. AB, J = 11.5 Hz, H-10’), 4.35 (1H, dd, J = 2.4, 1.5 Hz, H-6), 3.61 (1H, d, J =
3.7 Hz, H-9), 3.49 (1H, dd, J = 3.7, 1.5 Hz, H-8), 3.04 (1H, part A syst. AB, J = 13.3 Hz, H-3), 2.61 (1H, part B syst. AB,
J = 13.3 Hz, H-3’), 1.20-0-95 (2811, m, TIPDS).
13C-NMR (125MHz, CO(CD3)2): δ 166.9, 164.4, 134.1, 131.2, 130.5, 129.4, 78.5 (C-6), 72.4 (C-7), 68.7 (C-10), 67.5
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(C-5), 65.7 (C-4), 59.8 (C-9), 54.4 (C-8), 38.8 (C-3), 18.2, 18.1, 18.05, 17.7, 17.6, 17.5, 17.45, 15.3, 15.25, 14.4, 14.0.
IR (KBr): ν 3436, 3268 (shoulder), 2947, 2889, 2862, 1748, 1729, 1631, 1465, 1455, 1411, 1389, 1372, 1273, 1147,
1104, 1072, 1006, 942, 885, 825 cm-1.
LRMS (API-ES1): m/z. 1232 (2M+2Na)+, 1209 (2M+Na)+, 616 (M+Na)+, 594 (M+H)+.
LRMS (EI): m/z 593 (M+, 2), 561 (3), 550 (3), 534 (1), 459 (1), 440 (1), 428 (3), 413 (2), 384 (2), 365 (3), 339 (17), 289
(7), 261 (7), 235 (5), 175 (5), 163 (5), 147 (7), 135 (12), 119 (8), 105 (100), 77 (15).
E.A. (C28H43NO9Si2): Found: C, 56.75; H, 7.46; N, 2.57. Calculated: C, 56.63; H, 7.30; N, 2.36.
Example 6:
Preparation of rac-(4R,5S,6S,7S,8S,9S)-7-Benzoyloxymethyl-8,9-epoxy-5,6,7-trihydroxy-1-(N,N’-diisopropyl-
carbamidoylnxy)-5,6-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-diil)-1-azaspiro[3.5]nonan-2-one (74)
[0100]
Diisopropylcarbodiimide (10 ml, 0.057 mmol, 1.0 eq.) was added to a stirred solution of rac-(4R,5S,6S,7S,8S,9S)-7-
benzoyloxymethyl-8,9-epoxy-1,5,6,7-tetrahydroxy-5,6-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-diil)-1-azaspiro[3.5]no-
nan-2-one (73) (34 mg, 0.057 mmol, 1.0 eq.) in CH3CN (1 ml). After 36 hours, more diisopropylcarbodiimide (0.5 eq.)
was added and the resulting suspension stirred at room temperature for 3 days, after which, the solvent was removed
under reduced pressure to obtain rac-(4R,5S,6S,7S,8S,9S)-7-Benzoyloxymethyl-8,9-epoxy-5,6,7-trihydroxy-1-(N,N’-di-
isopropylcarbamimidoyloxy)-5,6-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-diil)-1-azaspiro[3.5]nonan-2-one (74) (30 mg,
yield 73%) as a white solid.
Rf- 0.62 (TLC, hexane/AcOEt, 2:1); 0.79 (TLC, hexane/AcOEt, 1:1).
1H-NMR (300MHz, CDCl3): δ 8.08 (2H, dm, J = 7.2 Hz, Bz), 7.58 (1H, tm, J = 7-4 Hz, Bz), 7.45 (2H, ddm, J = 7.4, 7.2
Hz, Bz), 6.16 (1H, s broad, NH), 4.91 (1H, part A syst. AB, J= 12.1 Hz, H-10), 4.76 (1H, h, J = 6.8 Hz, NCH(CH3)2),
4.56 (1H, part B syst. AB, J - 12.1 Hz, H-10’), 4.41 (111, s broad, H-5), 4.32 (1H, d, J = 2.5 Hz, H-6), 3.87 (1H, h, J =
6.3 Hz, NCH(CH3)2), 3.68 (1H, d, J = 3.7 Hz, H-8), 3.56 (1H, dd, J = 3.7, 1.0 Hz, H-9), 2.86 (1H, part A syst. AB broad,
J = 13.4 Hz, H-3), 2.84 (1H, s broad, IIO-C(7)), 2.69 (1H, part B syst. AB, J = 13.4 Hz, H-3’), 1.38 (3H, d, J = 6.8 Hz,
NCH(CH3)2), 1.25 (3H, d, J = 6.8 Hz, NCH(CH3)2), 1.18-0.96 (34H, m, TIPDS y NCH(CH3)2).
13C-NMR (75MHz, CDCl3): δ 169.0, 166.9, 146.4, 133.3, 129.7, 128.5, 74.4, 73.2, 66.2 63.1, 56.6, 55.8, 48.6, 46.4,
42.2, 40.8, 23.7, 23.5, 21.4, 19.4, 17.8, 17.6, 17.55, 17.5, 17.2, 17.15, 17.1, 16.8, 14.2, 13.8, 13.6, 13.3.
LRMS (API-ES+): m/z 1462 (2M+Na)+, 720 (M + H)+,
LRMS (EI): m/z 719 (M+, 0.2), 676 (2), 658 (1), 634 (2), 619 (3), 591 (2), 561 (3), 550 (2), 534 (2), 419 (3), 413 (2), 395
(2), 365 (4), 339 (24), 289 (6), 261 (11), 235 (4), 163 (5), 147 (6), 127 (18), 105 (100), 77 (16).
Example 7:
Preparation of rac-(4S,5R,6R,7R,8S,9S)-1-Bencyloxy-7-benzoyloxymethyl-6-tert-butyldimethylsyliloxy-5-cy-
ano-8,9-dihydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diil)-5,7-bis(methoxycarbonoyloxy)-1-azaspiro
[3.5]nonan-2-one (75)
[0101]
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[0102] To a solution of rac-(4S,6S,7R,8S,9S)-1-bencyloxy-7-benzoyloxymethyl-6-tert-butyldimethylsyliloxy-7,8,9-tri-
hydroxy-8,9-O-(1,1 ,3,3-tetraisopropyldisyloxane-1,3-diil)-1-azaspiro[3.5]nonane-2,5-dione (70) (85 mg, 0,104 mmol,
1.0 eq.) and methyl cyanoformiate (100 ml, 1.248 mmol, 12.0 eq.) in THF (1 ml) DABCO was added at room temperature
(3 mg, 0.026 mmol, 0.25 eq.). The resulting mixture was stirred at room temperature for 15 hours, after which solvent
was removed under reduced pressure. The residue was grinded with AeOEt, filtered through Celite and the solvent
removed under reduced pressure. The product was purified by silica gel column chromatography (hexane/AcOEt, 8:1)
and rac-(4S,5R,6R,7R,8S,9S)-1-Bencyloxy-7-benzoyloxymethyl-6-tert-butyldimethylsyliloxy-5 -cyano-8,9-dihydroxy-
8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diil)-5,7-bis(methoxycarbonoyloxy)-1-azaspiro[3.5]nonan-2-one (75) (29
mg, yield. 29%) was obtained as a white solid. An isomer was also isolated (5 mg, rto. 5%, Rf = 0.49 (TLC, hexane/
AcOEt, 3:1)).
Rf = 0.41 (TLC, hexane/AcOEt, 3:1).
1H-NMR (300MHz, CDCl3): δ 7.98 (2H, , J = 6.9 Hz, Bz), 7.61 (1H, J = 7.4 Hz, Bz), 7.53-7.41 (4H, m, Bz y Ph), 7.41-7.28
(3H, m, Ph), 5.56 (1H, d, J = 1.3 Hz, H-6), 5.14 (1H, dd, J = 4.0, 1.3 Hz, H-8), 5.08 (1H, part A syst. AB, J= 12.0 Hz, H-
10), 5.05 (1H, pare A syst. AB, J - 10.1 Hz, OCH–2Ph), 5.00 (1H, part B syst. AB, J = 10.1 Hz, OCH2Ph), 4.88 (1H, d, J
= 4.0 Hz, H-9), 4.83 (1H, part B syst. AB, J = 12.0 Hz, H-10’), 3.90 (3H, s, OCH3), 3.62 (3H, s, OCH3), 3.45 (1H, part
A syst. AB, J = 14.8 Hz, H-3), 3.05 (111, part B syst. AB, J = 14.8 Hz, H-3’), 1.16-0.88 (28H, m, TIPDS), 0.95 (9H, s, C
(CH3)3), 0.40 (3H, s, SiCH3), 0.23 (3H, s, SiCH3).
13C-NMR (75MHz, CDCl3): δ 167.0, 165.4, 152.9, 152.7, 135.3, 133.5, 129.4, 129.2, 128.9, 128.6, 128.3, 128.2, 115.1
(CN), 83.6 (C-7), 81.9 (C-5), 78.7, 71.0 (C-8), 68.7 (C-6), 66.5 (C-4), 65.2 (C-9), 61.9 (C-10), 55.8, 55.1, 38.8 (C-3),
26.4, 18.6, 17.6, 17.4, 17.3, 17.1, 17.0, 16.9, 16.8, 16.7, 13.5, 13.3, 13.1, 13.0, -3.3, -4.0.
IR (KBr): ν 3436, 2946, 2889, 2862, 2338, 1794, 1776, 1751, 1729, 1633, 1465, 1440, 1394, 1378, 1293, 1263, 1158,
1121, 1089, 1044, 995, 977, 922, 840, 785, 712 cm-1.
LRMS (API-ES+): m/z 1936 (2M+Na)+, 1915 (2M+H)1, 1029 (M+73)+, 957 (M+H)+.
Example 8:
Preparation of rac-(4R,5S,6S,9R)-1-benzyloxy-6-tert-butyldimethylsilyloxy-9-cyano-5-trimethylsilyloxy-1-aza-
spiro[3.5]nona-8-en-2,7-dione
[0103]
[0104] To a stirred solution of cyanotrimethyl silane (56ml, 0.411 mmol) and trimethylaluminium (0.19 ml, 2.0 M solution
in toluene, 0.374 mmol) in THF (0.5 ml) was added at room temperature a solution of rac-(4R,5S,6S)-1-benzyloxy-6-tert-
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butyldimethysilyloxy-5-trimethylsilyloxy-1-azaspiro[3.5]nona-8-en-2,7-dione (1) (89 mg, 0.187 mmol) in THF (0.5 ml).
The resulting mixture was stirred at reflux for 24 h and then concentrated under reduced pressure. The residue was
dissolved in toluene (2 ml), was washed with cold NH4Cl sat. (1 ml) and Na2HPO4 0.1 M buffer (1 ml), dried over Na2SO4,
filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-
AcOEt, 5:1) to give rac-(4R,5S,6S,9R)-1-benzyloxy-6-tert-butyldimethylsilyloxy-9-cyano-5-trimethylsilyloxy-1-azaspiro
[3.5] nona-8-en-2,7-dione (5) as a low melting point white solid (21 mg, 22%).
Rf = 0.41 (TLC, hexane-AcOEt, 3:1); yield, 22%; white solid.
1H-NMR (300MHz, CDCl3): δ 7.44-7.30 (5H, m, Ph), 5.31 (1H, part A syst. AB, J = 10.7 Hz, OCH2Ph), 5.11 (1H, part
B syst. AB, J = 10.7 Hz, OCH2Ph), 4.71 (1H, d, J = 2.2 Hz, H-6), 4.13 (1H, d, J - 2.2 Hz, H-5), 3.66 (1H, dd, J - 13.4,
5.4 Hz, H-9), 2.92 (1H, part A syst. AB, J = 14.5 Hz, H-3), 2.76 (1H, part B syst. AB, J - 14.5 Hz, H-3), 2.63 (1H, dd, J
= 13.4, 5.4 Hz, H-8), 2.21 (1H, t, J = 13.4 Hz, H-8), 0.85 (9H, s, C(CH3)3), 0.09 (9H, s, Si(CH3)3), 0.08 (3H, s, SiCH3),
-0.06 (3H, s, SiCH3),
13C-NMR (75MHz, CDCl3): δ 201.0, 164.1, 1.33.9, 129.5, 129.4, 128.9, 117.1, 80.8, 78-9, 78.0, 67.3 , 42.2, 38.3, 32.0,
25.8, 1 8,5, 0.5, -4.8, -5.6.
IR (KBr): ν 3425, 2956, 2927, 2855, 2233, 1772, 1631 , 1454, 1364, 1255, 1107, 1064, 841 cm-1.
LRMS(API-ES+): m/z 525(M+Na)+, 503(M+H)+.
Example 9:
Preparation of rac-(4R,5S,6S,9R)-9-Cyano-1,5,6-trihydroxy-5,6-O-(1,1,3,3-tetraisopropyidisiloxane-1,3-diil)-
1-azaspiro[3.5]nonane-2,7-dione (77)
[0105]
To a solution of rac-(4R,5S,6S,9R)-1-bencyloxy-9-ciano-5,6-dihydroxy-5,6-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-
dill)-1-azaspiro[3.5]nonanr-2,7-dione (76) (110 mg, 0.197 mmol, 1.0 eq.) in AcOEt (2 ml) Pd/C was added (13 mg, 10%
w/w, 0.012 mmol, 0.06 eq.) and the resulting suspension was stirred under hydrogen atmosphere for 1 hour. Afterwards
the mixture was filtered with celite and the catalyst was first washed with MeOH and then with AcOEt. Next, the solvent
was removed from the alcohol phase under reduced pressure and the residue purified by column chromatography
(hexane/AcOEt, 5:1). rac-(4R,5S,6S,9R)-9-Cyano-1,5,6-trihydroxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diil)-1-
azaspiro[3.5]nonane-2,7-dione (77) (27 mg, yield 29%) was obtained as a white solid. The AcOEt extract was also
evaporated under reduced pressure and starting material (7 mg, 6%, Rf = 0.62 (TLC, hexane/AcOEt, 3:1)) was recovered.
Rf = 0.20 (TLC, hexano/AcOEt, 3:1).
1H-NMR (300MHz, CDCl3): δ 10.5 (1H, s broad, OH), 5.25 (1 H, d, J = 2.4 Hz, H-5 o H-6), 4.54 (1H, d, J= 2.4 Hz, H-6
o H-5), 3.76 (1H, dd, J= 12.7, 5.5 Hz, H-8), 3.11 (1H, t, J = 13.8 Hz, H-9), 2.94 (1H, part A syst. AB, J = 14.2 Hz, H-3),
2-87 (1H, part B syst. AB, J = 14.2 Hz, H-3’), 2.79 (1H, dd, J = 14.4, 5.5 Hz, H-8’), 1. 16-0.88 (28H, m, TIPDS).
LRMS (API-ES+): m/z 960 (2M+Na)+, 491 (M+Na)1, 469 (M+H)+.
LRMS (EI): m/z 468 (M+, 9), 451 (4), 441 (1), 425 (100), 409 (12), 397 (13), 381 (19), 364 (33), 353 (6), 339 (39), 320
(36), 304 (13), 289 (10), 275 (43), 260 (15), 235 (23), 207 (12), 189 (18), 175 (17),163 (19), 147 (22), 135 (42), 119
(27), 105 (30), 91 (60), 77 (28).
Claims
1. A process for the synthesis of a compound of formula I:
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wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R5 is selected from H, OH, OPr;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R10 is selected from H, OH, OPr or -O;
R11 is H, Pr or a negative charge;
R12 is H or Prn;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S;
Ra and Rb are each independently selected from H, OH, OPr or substituted or unsubstituted alkyl, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
or its salts or tautomers,
comprising the step of forming a orthoester from a compound of formula VII:
wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R6, and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or -O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together are -O-
forming an epoxide ring;
R12 is H or Prn;
Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or un-
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substituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPm, NH, ⊕NH2, O or S.
2. A process for the synthesis of a compound of formula VII
wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
R9 and R10 are each independently selected from H, OH, OPr or -O;
R3 is selected from H, OH, OPr or =O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together arc -O-,
forming an epoxide ring;
R12 is H or Prn;
Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or un-
substituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
X1 is selected from NPm, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S;
which comprises opening the 1-aza-2-oxaspiro ring of a compound of formula VI
wherein X1, X2, R1, R2, R3, R5, R6, R7 R9, R10, Ra and Rb have the same meaning as in formula VII.
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3. A process for the synthesis of a compound of formula 1:
wherein
R1 and R2 together are -O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R5 is selected from H, OH, OPr;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R10 is selected from H, OH, OPr or =O;
R11 is H, Pr or a negative charge;
R12 is H or Prn;
X1 is selected from NPrn, NII, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S;
Ra and Rb are each independently selected from H, OH, OPr or substituted or unsubstituted alkyl, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
or its salts or tautomers,
comprising the following steps:
a) deprotecting the N-oxide residue of a compound of formula II
wherein
R3 and R9 are each independently selected from H, OH, OPr or =O;
R4 is selected from cyano, substituted or unsubstituted alkyl, OPr, substituted or unsubstituted alkenyl, substi-
tuted or unsubstituted alkinyl;
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R4 and R5 together are -O;
or R3 and R5 or R3 and R2 together are -O-, forming and epoxide ring;
W is a group comprising at least a group selected from substituted alkyl, substituted or unsubstituted aryl,
substituted or usubstituted heterocyclyl, substituted or unsubstituted alkenyl;
R1, R2, R10, Ra, Rb and Pr have the same meaning as in formula 1;
followed by the introduction of a residue of formula III
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wherein
X1 is selected from NHPrn, NH2, N(Prn)2, wherein Pm can be the same or different, OH, OPr, SH or SPrs;
X2 is selected from NPrn, NH, O or S;
Prs is a sulfur protecting group;
Pr and Prn have the same meaning as in formula 1;
to give a compound of formula IV
wherein
R1, R2, R3, R4, R5, R9, R10, Ra and Rb have the same meaning as in formula II;
X1 and X2 have the same meaning as in formula III;
b) closing the ring between X1 and either R4 or C4a of the compound of formula IV to give a compound of formula V
wherein
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S;
R1, R2, R3, R5, R9, R10, Ra and Rb have the same meaning as in formula II;
R6 and R7 have the same meaning as in formula 1;
c) if necessary, subjecting the compound of formula V to a rearrangement to give a compound of formula VI
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wherein
R1, R2, R3, R5, R6, R7, R9, R10, X1, X2, Ra and Rb have the same meaning as in formula V;
d) opening the 1-aza-2-oxaspiro residue of the compound of formula VI to give a compound of formula VII
wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl,
alkyl-OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubsti-
tuted alkinyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together are
-O-, forming an epoxide ring;
R12 is H or Prn;
Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted
or unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
X1 is selected from NPm, NH, O or S;
X2 is selected from NPm, NH, ⊕NH2, O or S; and
e) formation of the orthoester to give a compound of formula I from a compound of formula VII.
4. A process according to anyone of claims 1-3 wherein R6 is OH or OPr and R7 is H, or R6 and R7 together are -O.
5. A process according to anyone of claims 1-3 wherein R10 is OH or OPr.
6. A process according to anyone of claims 1-3 wherein X1 is N.
7. A process according to to anyone of claims 1-3 wherein R5 is H.
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8. A process according to claims 1 or 3 wherein the compound of formula I is TTX, its salts or tautomers thereof.
9. A process according to claims 1 or 3 wherein the step e) or formation of the orthoester is carried out by acid treatment.
10. A process according to claim 9 wherein the formation of the compound of formula I is carried out in two steps wherein
d1) the compound of formula VII is treated with acid to give a compound of formula VIIIa
wherein
R1, R2, R3, R5, R6, R7, R10, R12, X1, X2, Ra, Rb, Pr and Prn have the same meaning as in formula VII, if R9 is
OH or OPr; or
d2) the compound of formula VII is treated with acid to give a compound of formula VIIIb
wherein
R1, R2, R5, R6, R7, R9, R10, R12 X1, X2, Ra, Rb, Pr and Prn have the same meaning as in formula VII if R3 is
OH or Pr.
11. Use of a compound of formula II
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wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O;
R4 is selected from cyano, substituted or unsubstituted alkyl, OPr, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkinyl;
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or
R4 and R5 together are =O; or
R3 and R5 or R3 and R2 together are -O-, forming an epoxide ring;
W is a group comprising at least a group selected from substituted alkyl, substituted or unsubstituted aryl, substituted
or usubstituted heterocyclyl, substituted or unsubstituted alkenyl;
Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or un-
substituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
in the synthesis of tetrodotoxin, its tautomers, enantiomers or analogues.
12. Use according to claim 11 wherein the compound of formula 11 is selected from the group consisting of
compounds of formula IIa
compounds of formula IIb
compounds of formula IIc
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compounds of formula IId
compounds of formula IIc
wherein R1, R2, R3, Ra, Rb, W and OPr arc as defined in formula II.
13. A compound of formula VII
wherein
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R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R6 and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together are -O-,
forming an epoxide ring;
R12 is H or Prn;
Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or un-
substituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S.
14. A compound according to claim 13, of formula VIIa
wherein R1, R2 R5, R6, R7, R8, R12 Ra, Rb, X1, X2 and Pr are as defined claim 13.
15. A compound according to claim 13, of formula VIIb
wherein R1, R2 R6, R7, R8, R12 Ra, Rb, X1, X2 and Pr are as defined claim 13.
16. A compound of formula VI
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wherein R1 ,R2, R3, R5, R6, R7, R9, R10, Ra, Rb, X1 and X2 have the same meaning as in claim 13.
17. A compound according to claim 16, of of formula VIa
wherein R1, R5, R6, R7, Ra, Rb, X1, X2 and Pr are as defined in claim 16.
18. A compound according to claim 16, of of formula VIa
wherein R1, R6, R7, Ra, Rb, X1, X2 and Pr are as defined in claim 16.
19. A compound of formula V
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wherein R1, R2, R3, R5, R6, R7, R9, R10, Ra, Rb, X1 and X2 have the same meaning as in claim 13.
20. A compound according to claim 19, which has formula Va
wherein R1, R5, R6, R7, Ra, Rb, X1, X2 and Pr are as defined in claim 19.
21. A compound according to claim 19, which has formula Vb
wherein R1, R6, R7, Ra, Rb, X1, X2 and Pr are as defined in claim 19.
22. A compound of formula IV
wherein
R1 and R2 together are -O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O;
R4 is selected from cyano, substituted or unsubstituted alkyl, OPr, substituted or unsubstituted alkenyl, substituted
or unsubstituted alkinyl;
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or
R4 and R5 together are =O; or
R3 and R5 or R3 and R2 together are -O-, forming an epoxide ring;
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Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or un-
substituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or
unsubstituted amino or halogen;
X1 is selected from NHPrn, NH2, N(Prn)2, wherein Prn can be the same or different, OH, OPr, SH or SPrs;
X2 is selected from NPm, N H, O or S;
Pr is a hydroxyl protecting group
Prn is an amino protecting group
Prs is a sulfur protecting group.
23. A. process for the synthesis of a compound of formula 1:
wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-
OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkinyl,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R5 is selected from H, OH, OPr;
R6 and R7 together are -O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R10 is selected from H, OH, OPr or -O;
R11 is H, Pr or a negative charge;
R12 is H or Prn;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPrn, NH, ⊕NH2, O or S;
Ra and Rb are each independently selected from H, OH, OPr or substituted or unsubstituted alkyl, substituted or
unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
or its salts or tautomers,
comprising the following steps:
a) deprotecting the N-oxide residue of a compound of formula II
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wherein
R3 and R9 are each independently selected from H, OH, OPr or=O;
R4 is selected from cyano, substituted or unsubstituted alkyl, OPr, substituted or unsubstituted alkenyl, substi-
tuted or unsubstituted alkinyl;
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R4 and R5 together are =O;
or R3 and R5 or R3 and R2 together are -O-, forming and epoxide ring;
W is a group comprising at least a group selected from substituted alkyl, substituted or unsubstituted aryl,
substituted or usubstituted heterocyclyl, substituted or unsubstituted alkenyl;
R1, R2, R10, Ra, Rb and Pr have the same meaning as in formula 1;
followed by the introduction of a residue of formula III
wherein
X1 is selected from NHPrn, NH2, N(Prn)2, wherein Prn can be the same or different, OH, OPr, SH or SPrs;
X2 is selected from NPrn, NH, O or S;
Prs is a sulfur protecting group;
Pr and Prn have the same meaning as in formula I;
to give a compound of formula IV
wherein
R1, R2, R3, R4, R5, R9, R10, Ra and Rb have the same meaning as in formula II;
X1 and X2 have the same meaning as in formula III;
b) closing the ring between X1 and either R4 or C4a of the compound of formula IV to give a compound of
formula VI
wherein
R1, R2, R3, R5, R6, R7, R9, R10, X1, X2, Ra and Rb have the same meaning as in formula V;
c) opening the 1-aza-2-oxaspiro residue of the compound of formula VI to give a compound of formula VII
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wherein
R1 and R2 together are =O or alkenyl; or
R2 is selected from H, OH or OPr, and R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl,
alkyl-OPr, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubsti-
tuted alkinyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
R6, and R7 together are =O or =NPrn; or R6 and R7 are each independently selected from H, OH, OPr or cyano;
R8 is H, OH, ester or amide;
R9 and R10 are each independently selected from H, OH, OPr or =O;
R3 is selected from H, OH, OPr or =O,
if the bond between C5 and C4a is a single bond, R5 is selected from H, OH or OPr; or R3 and R5 together are
-O-, forming an epoxide ring;
R12 is H or Prn;
Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted
or unsubstituted amino or halogen;
Pr is a hydroxyl protecting group;
Prn is a amino protecting group;
X1 is selected from NPrn, NH, O or S;
X2 is selected from NPm, NH, ⊕NH2, O or S; and
d) formation of the orthoester to give a compound of formula 1 from a compound of formula VII.
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